Palvella Therapeutics (PVLA) logo

Palvella Therapeutics (PVLA) stock

Rare skin medicines , market cap $2.1B

$142.85
-2.00%

Quality Score
-2
Poor
In its industry
#125of 273
Checks firing
1of 14
Trending up
From 52-week high
-20.6%
under its best in a year

PVLA's Quality Score fell 3 points on Fri, Nov 20, to -2. Its week-by-week trend stopped pointing up (2 chart checks stopped).

Follow PVLA's trial news. Pro members can get an alert when Palvella Therapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when PVLA files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“Phase 3 trial initiation remains on track for the fourth quarter of 2026.”Trial start · SEC filing · Nov 5

Key facts on PVLA

Key facts on PVLA
Holding it back31.3% more shares than a year ago from Massive's market data
Latest filing8-K, Nov 5 Reported its quarterly results

PVLA in the news

Fri Nov 6What Palvella Therapeutics (PVLA) Said on Its Q3 Earnings Call Yahoo Finance PVLA closed +12.2% that day.

PVLA catalysts

Coming up

After its last 4 reports it closed +1.1% on average, higher 2 of 4 times.

4 more coming up and 6 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for PVLA, and how long its cash lasts

Next step the company has named

Q4 2026“Phase 3 trial initiation remains on track for the fourth quarter of 2026.”Trial start · SEC filing · Nov 5

What it means: when a trial begins, or reaches the stage the company named.

A trial underway
LOTUPhase 2 · Recruiting · 15 people · main data estimated Aug 2027 · NCT07552077

3 more trials, 4 more milestones and 42 filings, for Pro members.

Cash runway

The company says its cash lasts into 2H 2027 (8-K, Jan 29).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Jan 2, 2026)
  • At-the-market share sales program (S-3, filed Jan 2, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Chief Scientific Officer Jeffrey S. Martini sold 12,500 shares on Nov 11, under a planned sale. 16 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Wes Kaupinen’s 16 filings and quotes.

Get an alert when PVLA files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why PVLA scores -2

Poorfor quality, not price, 1 of 14 chart checks firingWhat the Quality Score means

Well below its recent run. PVLA scores -2 today, against a median of 5.5 over its last 20 recorded sessions.

  • +2Long-term trend above a rising 200-⁠day average
  • −2Dilution 31.3% more shares outstanding than a year ago, from Massive's market dataNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Chart checks adds
  • Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Growth, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on PVLA and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:34 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when PVLA's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How PVLA ranks in Biotech

PVLA is #125 of 273 by Quality Score.

How PVLA ranks in Biotech
RankStockQuality Score
125Palvella Therapeutics (PVLA) logoPVLAPalvella Therapeutics-2

Cash and short-term investments: PVLA $237M, RCUS $630M, KNSA $569M, XNCR $378M.

More in Biotech

When does PVLA report earnings, and what happens after?

Expected to report Wed Mar 31, before the open (in 130 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What PVLA reported on Nov 5, 2026

The quarter

The figures are not read from the release yet.

“The increase was primarily due to increased spending on manufacturing activities, the clinical development of QTORIN rapamycin for the treatment of angiokeratomas, costs associated with completion of the submission of the rolling NDA, and costs resulting from increased headcount and consulting services in 2026.”

The filing on EDGAR

Where the sales came from

PVLA's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The increase was primarily due to increased headcount in 2026, as well as increased professional services related to operating as a publicly-traded company.”

From its results filing (SEC filing · Nov 5)

The numbers

Market value
$2.1B
today

No analyst estimates on Breakaway: every figure here is filed.

The whole report on PVLA: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-13.0%+8.0%-3.4%
May 7Aug 4Nov 5
ReportedGapReaction5
days
Nov 5, 2026Before open+2.7%-3.4%+1.0%
Aug 4, 2026Before open-3.9%+8.0%+8.1%
May 7, 2026Before open-0.9%-13.0%-7.4%

PVLA closed higher after 2 of its last 4 reports.

All 4 reports, and PVLA's Quality Score going into each

PVLA has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on PVLA, and all 14 on every stock.Get in free →See the top 3 →Start Pro

PVLA RSI on Nov 20: 45.9, above its 50-day and 200-day averages

Not scored

RSI 45.9, MACD below signal, above both averages. Not scored.

The deep dive on PVLA

5 more findings on PVLA, each with its source, for Pro members.

PVLA share count over time

31% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of PVLA outstanding, as filed
Shares
outstanding
As
of
14.6MNov 2, 2026
14.4MJul 31, 2026
14.3MMay 1, 2026
14.3MMar 25, 2026
Offerings, shelves, and splits of PVLA, from its filings
From its
filings
Filed
Raised $200M in a sale of shares, about 9% of its market valueFeb 26, 2026
Registered shares for a later sale (S-3)Jan 2, 2026
Registered shares for sale (S-1)Dec 31, 2024
Priced a sale of sharesNov 8, 2024

PVLA insider trades

One insider sold $49K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellChristopher P. Kiritsy$49KDirectorat $157.00 on Sep 2, filed Sep 4

PVLA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.

29 employeesWayne, PApalvellatx.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on PVLA and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn PVLA's score around: 8 things
  • 8 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawaySep 4Christopher P. Kiritsy sold PVLA$49K at $157.00, filed Sep 4

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: PVLA's Quality Score is -2 (Poor), #125 of 273 in Biotech. Insiders sold $49K in the last 6 months (Form 4).

What does PVLA's Quality Score say?

PVLA scores -2 today, which Breakaway calls Poor. It is #125 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is PVLA's Quality Score?

PVLA scores -2 today, which Breakaway calls Poor (below zero). That is #125 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind PVLA's -2.

Are insiders buying PVLA?

One insider sold $49K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Christopher P. Kiritsy, Director, who sold $49K on Sep 2.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Palvella Therapeutics: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.